RoosterBio Inc

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our clients success and creating a world where...

Mesenchymal stem/stromal cells,bioprinting,tissue engineering,cell therapy,regenerative medicine,biomedical engineering,bioprocessing,process development,democratizing cell technologies,exosomes,extracellular vesicles ,advanced therapies,biotechnology,cell and gene therapy,stem cell research,and biomanufacturing

Roosterbio inc operates in the Biotechnology research industry.

Roosterbio inc's revenue is 11m - 100m

Roosterbio inc has 51 - 200 employees.